# Endotronix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endotronix

- Industry: Medical Devices & Equipment
- Headquarters: Naperville, US
- Website: www.endotronix.com
- Total disclosed funding: $52M
- Latest round: Series D (Sep 14, 2018)
- Investors on record: 8

## About

Based in the US, Endotronix, Inc. specializes in innovative digital health solutions for heart failure management, leveraging advanced technology to improve patient outcomes through remote monitoring and data-driven insights.Endotronix, Inc. focuses on heart failure management through its flagship product, the Cordella Pulmonary Artery (PA) Sensor System, which provides critical data for patient care. Founded in 2007 in Naperville, US, the company has undergone strategic pivots to enhance its offerings. Co-founders Anthony Nunez, Harry Rowland, and Michael Nagy have contributed to its development, with Harry Rowland currently serving as CEO. The company has raised a total of USD 20.250 mn, with its latest funding round being Series D led by EQT Life Sciences.Endotronix, Inc. primarily focuses on advancing heart failure management through its core offering, the Cordella Pulmonary Artery (PA) Sensor System. This FDA-approved medical device measures, records, and transmits pulmonary artery pressure data for patients with New York Heart Association (NYHA) Class III heart failure. The system enables remote monitoring and proactive management of heart failure by providing clinicians with comprehensive patient health data, including pulmonary artery pressure, blood pressure, weight, heart rate, and blood oxygen levels. The Cordella system assists healthcare providers in optimizing medication therapy and reducing hospitalizations, thereby improving patient outcomes and quality of life, primarily serving healthcare providers, caregivers, and patients across various markets, including the United States and select regions in Europe.Endotronix generates revenue through the sales of its Cordella PA Sensor System and associated services, focusing on a direct-to-consumer model targeted at healthcare institutions and clinics. The company's transactions include partnership agreements with healthcare providers and may explore subscription models for continuous monitoring services, facilitating ongoing support and data analysis for patients. The revenue model emphasizes integrating the Cordella system into existing care pathways, allowing clinicians to utilize real-time health data for effective treatment adjustments. As a prescription-only device in the U.S., its availability is restricted to orders from licensed physicians, positioning the company within a specialized medical device market catering to heart failure patients.Endotronix, Inc. plans to enhance its product offerings and expand into new markets. It aims to design and launch upcoming products that further improve heart failure management, though specific release dates are not detailed. The company is also targeting expansion into additional geographic regions beyond the U.S. and Europe. Recent funding of USD 20.250 mn from the Series D round will support these growth initiatives, including potential new product development and market entry strategies. Additionally, the firm has raised an undisclosed amount of venture funding from new investor MaasInvest, which could further bolster its expansion efforts.

## Funding rounds

- Series D, Sep 14, 2018, $20M — BioVentures Investors, EQT Life Sciences, Seroba, SV Health Investors, Aperture Venture Partners, OSF Ventures, Wanxiang Healthcare Investments, Lumira Ventures
- Series C, Jul 6, 2016, $32M — BioVentures Investors, SV Health Investors, Aperture Venture Partners, OSF Ventures, Lumira Ventures

## Investors

- BioVentures Investors (https://capitalatlas.ai/funds/bioventures-investors) — Series C, Series D
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series C, Series D
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series C, Series D
- OSF Ventures (https://capitalatlas.ai/funds/osf-ventures) — Series C, Series D
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series C, Series D
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series D
- Seroba (https://capitalatlas.ai/funds/seroba) — Series D
- Wanxiang Healthcare Investments (https://capitalatlas.ai/funds/wanxiang-healthcare-investments) — Series D